Marinus Pharmaceuticals (Marinus Pharmaceuticals) LT-Debt-to-Total-Asset : 0.36 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Marinus Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Marinus Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.36.

Marinus Pharmaceuticals's long-term debt to total assets ratio increased from Dec. 2022 (0.27) to Dec. 2023 (0.36). It may suggest that Marinus Pharmaceuticals is progressively becoming more dependent on debt to grow their business.

Marinus Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Marinus Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marinus Pharmaceuticals LT-Debt-to-Total-Asset Chart

Marinus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.31

0.27

0.36

Marinus Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.27	0.32	0.34	0.33	0.36

Marinus Pharmaceuticals LT-Debt-to-Total-Asset Calculation

Marinus Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	61.423	/	170.908
	=	0.36

Marinus Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	61.423	/	170.908
	=	0.36

Marinus Pharmaceuticals (NAS:MRNS) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Marinus Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Marinus Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Marinus Pharmaceuticals (Marinus Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marinus Pharmaceuticals Inc (NAS:MRNS) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

MRNS:Mexico 61Y:Germany

Address

100 Matsonford Road, Suite 500, 5 Radnor Corporate Center, Radnor, PA, USA, 19087

Website

https://www.marinuspharma.com

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Executives

Christina Shafer	officer: Chief Commercial Officer	5 RADNOR CORPORATE CENTER, SUITE 500, 100 MATSONFORD ROAD, RADNOR PA 19087
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Steven Pfanstiel	officer: CFO	5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Joseph Hulihan	officer: Chief Medical Officer	5 RADNOR CORP CENTER SUITE 500, 100 MATSONFORD RD, RADNOR PA 19087
Martha E Manning	officer: VP, Gen. Counsel & Corp. Sec.	700 PENNSYLVANIA DR, EXTON PA 19341
Sarah B. Noonberg	director	331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Marvin Johnson	director	C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Elan Ezickson	director	AVEO PHARMACEUTICALS, INC., 75 SIDNEY STREET, CAMBRIDGE MA 02139
Charles Austin	director	5 RADNOR CORPORATE CENTER STE 500, 100 MATSONFORD RD, RADNOR PA 19087
Fischer Seth H.z.	director	C/O TRIUS THERAPEUTICS, INC., 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Christine Berni Silverstein	director	C/O ABEONA THERAPEUTICS INC., 1330 AVENUE OF THE AMERICAS, 33RD FLOOR, NEW YORK NY 10019
Santiago Arroyo	director	C/O MOMENTA PHARMACEUTICALS, INC., 675 WEST KENDALL STREET, CAMBRIDGE MA 02142
Sara Nochur	director	295 WOODCLIFF RD, NEWTON MA 02461
Nicole Vitullo	director, 10 percent owner	3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Edward F Smith	officer: Chief Financial Officer	C/O POLYMEDIX, INC., 3701 MARKET STREET, PHILADELPHIA PA 19104